Innopharma, Inc.: Series A $15M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - Device (Delivery), X - Generics, X - Injectable, X - Opthalmology, XX - NJ

Innopharma (Piscataway, NJ) a development-stage specialty pharmaceutical company focused on generics and drug delivery technology platforms for existing drugs, closed a $15M Series A financing. Participants include Thomas, McNerney & Partners.

Oct

2010

OnBioVC Post 1,000 AxioMed Spine Corp.: Series D $15M

Posted in I - Series D, Q - 3Q10, R - MID WEST, X - Device (Spine), XX - OH

And cue the confetti cannon as we celebrate the 1,000th OnBioVC.com post!

AxioMed Spine (Cleveland, OH) a clinical-stage medical device company focused on lumbar disc replacement, closed a $15M Series D financing. Participants have included Thomas, McNerney & Partners, CID Equity Partners, Early Stage Partners, Investor Growth Capital, MB Venture Partners, Primus Capital Funds and Reservoir [...]

Sep

2010

Celator Pharmaceuticals, Inc.: Series D $20M

Posted in I - Series D, Q - 3Q10, R - NORTH EAST, X - Oncology, X - Therapeutic Platform, XX - NJ

Celator Pharmaceuticals (Princeton, NI) a clinical-stage small molecule company focused on acute myeloid leukemia and colorectal cancer, closed a $20M Series D financing. Participants have included Thomas McNerney & Partners, BDC Venture Capital, Domain Associates, GrowthWorks Capital, Quaker BioVentures, TL Ventures and Ventures West.

May

2010

NeuroTherapeutics Pharma, Inc.: Series B $43M

Posted in I - Series B, Q - 2Q10, R - MID WEST, X - CNS, X - Epilepsy, X - Pain, XX - IL

NeuroTherapeutics Pharma (Chicago, IL) a clinical-stage biopharmaceutical company focused on the CNS disorders of epilepsy, acute and neuropathic pain, closed a $43M Series B financing. Participants include Fidelity Biosciences, MPM Capital, S.R. One, Pfizer, Novo Ventures and Thomas McNerney & Partners.

Feb

2010

Zogenix, Inc.: Series B $20M

Posted in I - Series B, Q - 4Q09, R - WEST, X - Device (Delivery), X - Drug:Device Combo, XX - CA

Zogenix (San Diego, CA) a clinical-stage drug:device company focused on a needle-free delivery system of chronic pain therapeutics, closed a $20M Series B financing, bringing the total round to $71M. Participants have included Chicago Growth Partners, Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas McNerney & Partners, Oxford Finance and Abingworth Management.
Note: 2009 Year-in-Review Trend [...]

Feb

2010

Altair Therapeutics, Inc.: Series B $17M

Posted in I - Series B, Q - 4Q09, R - WEST, X - Asthma, X - Respiratory, X - Rhinitis, XX - CA

Altair Therapeutics (San Diego, CA) a clinical-stage biopharmaceutical company focused on antisense therapeutics for asthma and rhinitis, closed a $17M Series B financing. Participants include Domain Associates, AgeChem Venture Fund, Thomas McNerney & Partners and Forward Ventures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Oct

2009

Zogenix, Inc.: Series B $36M

Posted in I - Series B, Q - 3Q09, R - WEST, X - Device (Delivery), X - Drug:Device Combo, X - Pain, XX - CA

Zogenix (San Diego, CA) a clinical-stage drug:device company focused on a needle-free delivery system of chronic pain therapeutic, closed a $51M Series B financing. Participants include Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Oxford Finance and Abingworth Management.

to top of page...